Company Update (NASDAQ:IONS): Ionis Pharmaceuticals Inc and Akcea Announce Positive Results from Compass Phase 3 Study of Volanesorsen


Ionis Pharmaceuticals Inc (NASDAQ:IONS) and its wholly-owned subsidiary Akcea Therapeutics announced that the Phase 3 COMPASS study met its primary endpoint.  COMPASS is a randomized, double-blind, placebo-controlled, 26-week Phase 3 study evaluating volanesorsen in 113 patients with severe hypertriglyceridemia.  The average incoming triglyceride level of patients in the study was 1,261 mg/dl.  Patients treated with volanesorsen experienced clinically meaningful benefits on triglycerides as summarized below:

  • For the primary endpoint of the study, volanesorsen-treated patients (n=75) achieved a statistically significant (p<0.0001) mean reduction in triglycerides of 71.2% from baseline after 13 weeks of treatment, compared with a mean reduction of 0.9% in placebo-treated patients (n=38).  This represented a mean absolute reduction of 869 mg/dl in treated patients.  The treatment effect observed was sustained through the end of the 26 week treatment period.
  • In a subset of seven patients with familial chylomicronemia syndrome (FCS), whose average incoming triglyceride level was 2,280 mg/dl, volanesorsen-treated patients (n=5) achieved a mean reduction in triglycerides of 73% from baseline after 13 weeks of treatment, compared with a mean increase of 70% in placebo-treated patients (n=2).  This represented a mean absolute reduction of 1,511 mg/dl in treated patients.  The treatment effect observed was sustained through the end of the 26-week treatment period.
  • In addition, 82% of patients treated with volanesorsen, including three of the FCS patients, achieved triglyceride levels less than 500 mg/dl after 13 weeks of treatment, compared to 14% of placebo-treated patients (p<0.0001).

The COMPASS study is an important component of the planned regulatory filings for volanesorsen, an antisense drug designed to decrease triglyceride levels by directly targeting apolipoprotein C-III (ApoC-III), being developed for the treatment of patients with FCS and familial partial lipodystrophy (FPL), two rare metabolic disorders.  Ionis and Akcea management plan to discuss the results from this study at an upcoming Ionis pipeline update call on January 5, 2017, and also to present additional data from the study at an upcoming medical meeting.

“Current therapies are inadequate for patients with extremely high triglycerides, most specifically those with FCS, leaving them at risk for significant morbidity and mortality, including pancreatitis,” said Daniel Gaudet, M.D., associate professor of medicine and director of the Community Genomic Medicine Center, Department of Medicine, Université de Montréal and scientific director and strategic development officer of BioBank, Genome Quebec’s Technological Centers.  “People with FCS have particular challenges because in addition to having triglyceride levels that can be 10 to 20 times normal values, the currently available triglyceride-lowering drugs are usually ineffective.  The data from studies in patients with FCS treated with volanesorsen, including those from the COMPASS study, show that for the first time these patients can achieve the triglyceride reductions needed to potentially improve their health.”

COMPASS results were consistent with findings from the Phase 2 program for volanesorsen, which were published twice in the New England Journal of Medicine.  In the three FCS patients profiled in one publication, the incoming average triglyceride number was 1,844 mg/dl, and the average triglyceride reduction after three months of dosing with volanesorsen was 1,298 mg/dl.  In the COMPASS study, the average incoming triglyceride level of the five FCS patients treated with volanesorsen was 2,134 mg/dl, and the average triglyceride reduction was 1,511 mg/dl after three months of dosing.

“The findings in COMPASS reinforce the efficacy and safety of volanesorsen observed in Phase 2 studies across multiple patient populations, including FCS,” said Dr. Louis O’Dea, chief medical officer for Akcea.  “No drug available today has demonstrated the magnitude of the triglyceride reductions observed with volanesorsen.  These results confirm the potential value of targeting ApoC-III to lower triglycerides in patients who have high unmet need with potentially life-threatening consequences.”

The most common adverse event in the volanesorsen-treated group of patients was injection site reactions (ISRs), which were mostly mild.  In this study with patients who are largely asymptomatic and, unlike FCS patients, do not need to manage the daily burden and symptoms of their disease, 13% of treated patients discontinued due to ISRs and 7% of treated patients discontinued treatment for other non-serious adverse events.  There were no deaths in the study.  None of the FCS patients in the study discontinued.  In addition, there were no serious platelet events in the study.  There was one potentially related SAE on the drug-treated arm.  This was a report of serum sickness that occurred two weeks after the last study dose and resolved without treatment, and after thorough investigation the sponsor determined that the case was not likely caused by the drug.

Including COMPASS, four global trials form the Phase 3 program for volanesorsen.  Akcea plans to have top-line data from the pivotal APPROACH study in patients with FCS in the first quarter of 2017.  Akcea plans to have data from the pivotal BROADEN study in patients with FPL in 2019.  Patients with FCS who have completed or meet the study criteria for the APPROACH and COMPASS studies can enroll in an open-label extension (APPROACH OLE) study.  Patients in the BROADEN study are also eligible to roll over into an open-label extension study upon completing dosing in the pivotal study.

“The success of COMPASS represents an important milestone towards our planned regulatory filings for volanesorsen in the U.S., Europe and Canada in 2017,” said Paula Soteropoulos, president and chief executive officer of Akcea Therapeutics.  “As we complete this and other ongoing preparatory regulatory and pre-commercial activities, we are gratified to see clinical data that support this therapy’s potential to help the patients who have shared with us the severe challenges and fear with which they live, and the life-changing benefit a new therapy could potentially represent.”
(Original Source)

Shares of Ionis Pharmaceuticals closed last Friday at $49.30, down $0.35 or -0.70%. IONS has a 1-year high of $62.68 and a 1-year low of $19.59. The stock’s 50-day moving average is $41.85 and its 200-day moving average is $32.43.

On the ratings front, Ionis Pharmaceuticals has been the subject of a number of recent research reports. In a report issued on November 20, Leerink Swann analyst Paul Matteis reiterated a Hold rating on IONS. Separately, on November 14, Piper Jaffray’s Joshua Schimmer reiterated a Buy rating on the stock and has a price target of $51.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Paul Matteis and Joshua Schimmer have a yearly average return of 8.7% and a loss of -5.7% respectively. Matteis has a success rate of 54% and is ranked #533 out of 4283 analysts, while Schimmer has a success rate of 40% and is ranked #4142.

Sentiment on the street is mostly bullish on IONS stock. Out of 8 analysts who cover the stock, 4 suggest a Buy rating , 3 suggest a Hold and one recommends to Sell the stock.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of antisense drug discovery. It operates its business through the Ionis Core and Akea Therapeutics segments. The Ionis Core segment involves a a novel drug discovery platform generate a broad pipeline of drugs. The Akea Therapeutics segment develops and commercializes drugs for cardiometabolic disorders.